IPOS COPY
0102959-4

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [7]: A61K 31/675, A61P 31/12, A61K 9/20, 47/02 — A2

(11) International Publication Number: **WO 00/35460**

(43) International Publication Date: 22 June 2000 (22.06.00)

(21) International Application Number: PCT/US99/29626

(22) International Filing Date: 14 December 1999 (14.12.99)

(30) Priority Data:

09/211,613	15 December 1998 (15.12.98)	US
60/112,403	15 December 1998 (15.12.98)	US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US	09/211,613 (CON)
Filed on	15 December 1998 (15.12.98)
US	60/112,403 (CON)
Filed on	15 December 1998 (15.12.98)

(71) Applicant *(for all designated States except US)*: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DAHL, Terrence, C. [US/US]; 1646 Kennewick Drive, Sunnyvale, CA 94087 (US). YUAN, Lung-Chi, J. [US/US]; 207 Town Green Lane, Foster City, CA 94404 (US).

(74) Agents: HENSLEY, Max, D. et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: PHARMACEUTICAL FORMULATIONS

(57) Abstract

The invention provides compositions comprising the nucleotide analog 9 -[2 -[[bis[(pivaloyloxy) methyl]phosphono] methoxy] ethyl] adenine and an alkaline excipient with or without L-carnitine-L-tartrate. The compositions are more stable than those previously described. The invention also provides methods to make the compositions and their intermediates.